Investigating the use of statins to prevent heart disease in people with HIV
Official title: 2/2 REPRIEVE Extension for Trial Completion
Funded at Massachusetts General Hospital · NIH-11086718 · Data updated 2026-11-12
This study is looking at whether taking statins can help prevent heart problems in people living with HIV who aren't at high risk, and it's for those who want to contribute to important research about heart health in the HIV community.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts General Hospital NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | May 1, 2023 |
| Project end | April 30, 2026 |
| Funding year | 2025 |
| Award (this year) | $476,233 |
| NIH project number | 5U24HL164284-03 |
| Project ID | NIH-11086718 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals living with HIV who do not have known cardiovascular disease and are assessed to have low to moderate cardiovascular risk.
✕Less likely to help
Patients with known cardiovascular disease or those not living with HIV may not benefit from this research.
What this research studies
This research focuses on the REPRIEVE trial, which aims to determine if statins can effectively prevent cardiovascular disease in individuals living with HIV who are at low to moderate risk. The study will extend for two additional years to gather more data on major adverse cardiovascular events (MACE) to ensure the findings are robust. Participants will be monitored for changes in heart health and other related biomarkers through advanced imaging techniques and blood tests. This trial is significant as it leverages existing infrastructure to maximize the value of previous investments in HIV research.
Why it matters
Potential benefit: If successful, this research could lead to improved cardiovascular health and prevention strategies for individuals living with HIV.
How similar studies have gone: Previous studies have shown promise in using statins for cardiovascular prevention, making this approach both relevant and potentially impactful.
Where this research is happening
-
Massachusetts General Hospital
Boston, United States Active
Researchers
- Principal investigator: Lu, Michael Tse-Yin — Massachusetts General Hospital
- Study coordinator: Lu, Michael Tse-Yin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.